The latest FDA findings have renewed concerns about India's drug quality, after inspectors identified serious data integrity violations, discarded manufacturing records, and unacceptable hygiene conditions at pharmaceutical facilities.
Glenmark Pharma reported a sharp 56.78% year-on-year decline in consolidated net profit to Rs 263.83 crore in Q2 FY27, reflecting significant pressure on its quarterly earnings.
Two new studies published in JAMA and JAMA Pediatrics reveal a clear rise in infant bleeding cases linked to vitamin K deficiency.
Head and neck cancer patients with advanced disease have waited a decade for a new targeted treatment breakthrough after platinum-based chemotherapy.
Dr. Reddy's secures Brazilian regulatory approval for semaglutide, entering a competitive diabetes treatment market with USD 244.6 million in estimated commercial potential.
Lupin Q2 FY27 results reveal a 22% net profit decline despite revenue growth, highlighting rising expenses and margin pressures.
Hikma's branded drug growth is strengthening its 2026 outlook, with cardiovascular, diabetes and CNS medicines gaining momentum despite continued weakness in injectables revenue.
Evommune's USD 1.1 billion Hinova deal advances a VAV1 degrader targeting autoimmune diseases, putting protein degradation technology and rheumatoid arthritis development in focus.
Alembic Pharma’s Q2 surge highlights a changing growth engine, with US formulations, domestic branded medicines and API operations driving earnings.
AstraZeneca’s 10 billion bid for Rhythm Pharmaceuticals highlights how obesity science is becoming a strategic priority beyond mainstream weight-loss treatments.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
